Genentech’s first implantable drug delivery system shows promising results in phase 2 wet AMD trial | FierceBiotech
Jul 30, 2018 @ 9:44

Genentech’s investigational, refillable eye implant—designed to deliver a new formulation of Lucentis’ active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients—showed positive results in a phase 2 trial compared to the traditional delivery method.

Sourced through from:

Leave a Reply